中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.013 seconds)

    Fiber optic multitasking probe
    2.
    发明授权
    Fiber optic multitasking probe 失效
    光纤多任务探头

    公开(公告)号：US06514277B1

    公开(公告)日：2003-02-04

    申请号：US09329998

    申请日：1999-06-11

    Applicant: Lothar Lilge ,  David Walsh

    Inventor： Lothar Lilge ,  David Walsh

    IPC: A61B1822

    CPC classification number: G01N21/7703 ,  A61N5/0601 ,  A61N5/062 ,  G01N21/6428 ,  G01N2201/0846 ,  G01N2201/088

    Abstract: A multitasking optical fiber probe for collecting dosimeter information from more than one position in a sample. The basic principle of the present invention involves using one or more different sensor zones along the length of the fiber each with a different photoactive constituent having a sufficiently unique emission spectra (spectral or temporal) to enable deconvolution of the emission spectra by the computer and therefore correlation of the detected parameter with the position of the sensor zone along the length of the optical fiber. In the broadest form of the invention the probe is embodied by only one sensor zone located at some point along the length of the fiber spaced away from the end face of the fiber. Probes are provided in which multiple sensor zones are disposed along the length of the fiber and photoactive constituents with sufficiently unique emission spectra (intensity and/or spectral shape which convey the optical information) are used in the different sensor zones so that the different spectra can be deconvoluted so that the contributions from the various etch zones can be distinguished. More than one different photoactive constituent could be incorporated into a single sensor zone for measuring several factors in the vicinity of the sensor zone. In photodynamic therapy applications the probe is isotropic in response and can be employed for all light (300 to 900nm) based medical diagnostics and therapeutics. As an extension the probe can include photosensitiser and molecular oxygen concentrations dosimetry to be used for photodynamic therapy (PDT) treatment monitoring, dosimetry and planning utilizing a mathematical model describing tissue response to PDT.

    Abstract translation: 一种用于从样品中多于一个位置收集剂量计信息的多任务光纤探针。 本发明的基本原理涉及沿着纤维的长度使用一个或多个不同的传感器区域，每个具有不同的光活性组分具有足够独特的发射光谱（光谱或时间），以使计算机能够对发射光谱进行去卷积，因此 检测参数与传感器区域沿着光纤长度的位置的相关性。 在本发明的最广泛形式中，探针仅通过位于沿纤维长度的某一点处的一个传感器区域，该距离与纤维的端面间隔开。 提供探针，其中多个传感器区域沿着纤维的长度设置，并且光​​活性组分具有足够独特的发射光谱（传递光学信息的强度和/或光谱形状）被用于不同的传感器区域，使得不同的光谱可以 被去卷积，从而可以区分来自各种蚀刻区域的贡献。 可以将多于一种不同的光活性成分结合到单个传感器区域中，以测量传感器区域附近的几个因素。 在光动力学治疗应用中，探针是各向同性的响应，可用于所有基于光（300至900nm）的医疗诊断和治疗。 作为延伸，探针可以包括用于光动力治疗（PDT）治疗监测，剂量测定和计划的光敏剂和分子氧浓度剂量学，其使用描述对PDT的组织反应的数学模型。

    Optical transillumination and reflectance spectroscopy to quantify disease risk
    5.
    发明授权
    Optical transillumination and reflectance spectroscopy to quantify disease risk 有权
    光学透照和反射光谱来量化疾病风险

    公开(公告)号：US08224426B2

    公开(公告)日：2012-07-17

    申请号：US10496108

    申请日：2002-11-20

    Applicant: Lothar Lilge ,  Brian C. Wilson ,  Michelle K. Nielsen

    Inventor： Lothar Lilge ,  Brian C. Wilson ,  Michelle K. Nielsen

    IPC: A61B6/00

    CPC classification number: A61B5/4312 ,  A61B5/0091

    Abstract: The present invention uses spectroscopic tissue volume measurements using non-ionizing radiation to detect pre-disease transformations in the tissue, which increase the risk for this disease in mammals. The method comprises illuminating a volume of selected tissue of a mammal with light having wavelengths covering a pre-selected spectral range, detecting light transmitted through, or reflected from, the volume of selected tissue, and obtaining a spectrum of the detected light. The spectrum of detected light is then represented by one or more basis spectral components, an error term, and an associated scalar coefficient for each of the basis spectral components. The associated scalar coefficient is calculated by minimizing the error term. The associated scalar coefficient of the each of the basis spectral components is correlated with a pre-selected property of the selected tissue known to be indicative of susceptibility of the tissue for the pre-selected disease to obtain the susceptibility for the mammal to developing the pre-selected disease.

    Abstract translation: 本发明使用非电离辐射的光谱组织体积测量来检测组织中的疾病前变化，这增加了哺乳动物中该疾病的风险。 该方法包括用具有覆盖预选光谱范围的波长的光照射哺乳动物的体积的选定组织，检测透射通过选定组织的体积或从所选择的组织的体积反射的光，并获得检测到的光的光谱。 然后，检测到的光谱由一个或多个基础光谱分量，误差项和每个基本光谱分量的相关标量系数表示。 通过最小化误差项来计算相关联的标量系数。 每个基础光谱分量的相关联的标量系数与所选择的组织的预先选择的性质相关联，所述组织已知指示预先选择的疾病的组织的易感性，以获得哺乳动物开发前体的易感性 选择性疾病

    Optical transillumination and reflectance spectroscopy to quantify disease risk
    9.
    发明申请
    Optical transillumination and reflectance spectroscopy to quantify disease risk 有权
    光学透照和反射光谱来量化疾病风险

    公开(公告)号：US20060173352A1

    公开(公告)日：2006-08-03

    申请号：US10496108

    申请日：2002-11-20

    Applicant: Lothar Lilge ,  Brian Wilson ,  Michelle Nielsen

    Inventor： Lothar Lilge ,  Brian Wilson ,  Michelle Nielsen

    IPC: A61B6/00

    CPC classification number: A61B5/4312 ,  A61B5/0091

    Abstract: The present invention uses spectroscopic tissue volume measurements using non-ionizing radiation to detect pre-disease transformations in the tissue, which increase the risk for this disease in mammals. The method comprises illuminating a volume of selected tissue of a mammal with light having wavelengths covering a pre-selected spectral range, detecting light transmitted through, or reflected from, the volume of selected tissue, and obtaining a spectrum of the detected light. The spectrum of detected light is then represented by one or more basis spectral components, an error term, and an associated scalar coefficient for each of the basis spectral components. The associated scalar coefficient is calculated by minimizing the error term. The associated scalar coefficient of the each of the basis spectral components is correlated with a pre-selected property of the selected tissue known to be indicative of susceptibility of the tissue for the pre-selected disease to obtain the susceptibility for the mammal to developing the pre-selected disease.

    Abstract translation: 本发明使用非电离辐射的光谱组织体积测量来检测组织中的疾病前变化，这增加了哺乳动物中该疾病的风险。 该方法包括用具有覆盖预选光谱范围的波长的光照射哺乳动物的体积的选定组织，检测透射通过选定组织的体积或从所选择的组织的体积反射的光，并获得检测到的光的光谱。 然后，检测到的光谱由一个或多个基础光谱分量，误差项和每个基本光谱分量的相关标量系数表示。 通过最小化误差项来计算相关联的标量系数。 每个基础光谱分量的相关联的标量系数与所选择的组织的预先选择的性质相关联，所述组织已知指示预先选择的疾病的组织的易感性，以获得哺乳动物开发前体的易感性 选择性疾病

    Therapeutic laser device and method including noninvasive subsurface monitoring and controlling means
    10.
    发明授权
    Therapeutic laser device and method including noninvasive subsurface monitoring and controlling means 有权

    公开(公告)号：US06344051B1

    公开(公告)日：2002-02-05

    申请号：US09370315

    申请日：1999-08-09

    Applicant: Roger J. Dumoulin-White ,  Lothar Lilge ,  Robert A. Weersink

    Inventor： Roger J. Dumoulin-White ,  Lothar Lilge ,  Robert A. Weersink

    IPC: A61N5006

    Abstract: A method is provided for treating a patient having a disorder, wherein the method includes irradiating a tissue surface of the patient with at least one laser beam, automatically monitoring the tissue, and automatically controlling the at least one laser beam to adjust and/or terminate the treatment in a therapeutically effective manner. The method noninvasively determines in real-time the irradiance and/or radiant exposure of a target tissue at a predetermined depth below the tissue surface by detecting the radial dependence of light remitted from the tissue surface. Preferably, the method employs a near-infrared light laser beam and a visible laser light beam in combination. An apparatus for performing the method is also provided.

Patent Agency Ranking